whitepaper
Whitepaper: Buying a digital informatics system for your R&D?
Examining existing R&D processes with a consolidated approach enables the stop of disjointed workflows to engage on the digitisation journey.
List view / Grid view
Big Data
article
Digital revolution – not evolution – is the route to building back stronger after COVID-19
With a return to the workplace on the horizon for an increasing number of scientists, Richard Goodwin considers how COVID-19 will impact the ways research is conducted. One outcome he posits is the acceleration of the digital transformation that was already occurring in pharmaceutical R&D.
news
Analysis of proteomic data reveals potential therapeutic targets for cancer
Researches have provided a proof-of-concept that proteomic analysis could be used to identify drivers of aggressive cancers.
news
Novel AI tool takes a DeepCE dive into potential drugs for COVID-19
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.
news
New database to track neurological symptoms of COVID-19
NeuroCOVID will be a resource of clinical information and biospecimens from people who experience neurological problems associated with SARS-CoV-2 infection.
news
New database could inform the development of treatments to slow ageing
The database could save substantial resources for those wanting to do pre-clinical studies of interventions for age-related diseases, said scientists.
article
AI advancing drug discovery: the future is multi-cellular studies
Drs Sam Cooper and Michael Briskin of Phenomic AI, discuss how artificial intelligence (AI) is enabling them to target multi-cellular interactions, such as those in the tumour stroma, for drug development.
article
Unlocking the power of the microbiome in life sciences R&D
Anthony Finbow explains how applying microbiome-based evidence to disease modelling will enable researchers to devise more targeted treatments.
news
New ARRIVE 2.0 guidelines published to improve animal research
The ARRIVE 2.0 guidelines outline what researchers should include in reports to increase reproducibility and reliability for peer-review, and reduce certain ethical concerns surrounding the use of animals in research.
article
Using big data approaches to develop cell therapies
An area where stem cell biology and medicine are combining effectively is the establishment of new cell therapies. However, current therapies are limited to a narrow set of cell types that can be isolated or created and expanded in vitro. Dr Owen Rackham discusses how utilising computational approaches will further…
article
Data, data and still more data: the challenges of imaging and analysing 3D cell models
The latest generation of three-dimensional (3D) cell models offer new and exciting possibilities for pharmaceutical research. However, deciding how to capture sufficient information in the most efficient way from an experiment without making the data size overwhelming can prove challenging. Margaritha Mysior and Jeremy Simpson discuss the opportunities and challenges…
article
If Columbus had a map… guiding the discovery of new drugs
Exploring large databases and selecting compounds of interest can be extremely time-consuming for researchers. Here, Sacha Javor, Horst Flotow and Jingwen Shi discuss a novel chemoinformatics approach for drug discovery.
news
First studies of human genetic variation released by the gnomAD Consortium
The Genome Aggregation Database (gnomAD) Consortium has released seven papers leveraging its database to study genetic variants and their potential for guiding discovery of safer drugs.
article
Stem Cells In-Depth Focus 2020
The stem cells in-depth focus includes articles on using computational approaches to expand the applications of stem cell therapies and how organoids could be used to speed up the drug discovery process with a focus on retinal disease.
news
Free to use COVID-19 Protein Portal launched for researchers in UK
The COVID-19 Protein Portal, established by UKRI and Wellcome, will allow scientists in the UK to access protein reagents needed for research.
